Artivion (NYSE:AORT) Issues Earnings Results

Key Points

• Artivion exceeded quarterly expectations: Revenue rose 9% year over year to $125.8 million, above the $120.0 million analyst estimate, while earnings were $0.13 per share and adjusted EBITDA increased 7% to $26.4 million.
• Growth opportunities are expanding: FDA approval for AMDS is expected to support broader adoption, while the completed Endospan acquisition will enable a U.S. launch of the NEXUS aortic arch system in January 2027.
• Financial risks remain: Artivion maintained its 2026 guidance, but reported negative $12 million in second-quarter free cash flow, higher net leverage of 3.1, a pending $25 million AMDS milestone payment, and manufacturing and geopolitical risks linked to Endospan.

Artivion (NYSE:AORT - Get Free Report) announced its quarterly earnings data on Thursday. The company reported $0.13 earnings per share for the quarter, FiscalAI reports. The company had revenue of $125.76 million during the quarter, compared to analyst estimates of $119.99 million. Artivion had a net margin of 2.55% and a return on equity of 7.15%.

Here are the key takeaways from Artivion's conference call:

• Q2 revenue increased 9% year over year to $125.8 million, while adjusted EBITDA rose 7% to $26.4 million. Stent graft revenue accelerated 12% and On-X revenue grew 18%, both despite tougher comparisons.
• Artivion received FDA PMA approval for AMDS in June, removing IRB-related hurdles and expanding permitted marketing claims; management expects adoption and U.S. account conversions to accelerate gradually in the second half rather than through an immediate surge.
• The company completed its Endospan acquisition and plans a full U.S. launch of the FDA-approved NEXUS aortic arch system in January 2027. Management views NEXUS, AMDS, On-X, and the ARTIZEN pipeline as collectively representing roughly $430 million in current U.S. market opportunity.
• Artivion reiterated 2026 guidance for 7%–11% constant-currency revenue growth, or $480 million–$496 million, and adjusted EBITDA of $92 million–$99 million. The outlook assumes minimal NEXUS revenue this year, continued preservation-services timing and supply constraints, and roughly $8 million of Endospan-related expenses.
• Free cash flow was negative $12 million in Q2, while net leverage rose to 3.1 following $150 million of borrowing to fund the Endospan acquisition; the company also expects the $25 million AMDS milestone payment in Q3 and remains exposed to manufacturing and geopolitical risks tied to Endospan’s Israel facility.

Artivion Stock Up 1.4%

AORT traded up $0.37 during trading on Thursday, hitting $26.54. The stock had a trading volume of 1,122,145 shares, compared to its average volume of 560,268. The company has a market capitalization of $1.29 billion, a PE ratio of 110.60 and a beta of 1.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86. The stock has a 50 day simple moving average of $23.42 and a two-hundred day simple moving average of $31.16. Artivion has a twelve month low of $19.16 and a twelve month high of $48.25.

Insider Activity

In related news, SVP Andrew M. Green sold 44,001 shares of the firm's stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the transaction, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. This trade represents a 42.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Artivion

Institutional investors and hedge funds have recently modified their holdings of the company. Verition Fund Management LLC lifted its position in Artivion by 1.6% during the third quarter. Verition Fund Management LLC now owns 16,912 shares of the company's stock worth $716,000 after buying an additional 274 shares in the last quarter. Entropy Technologies LP raised its holdings in shares of Artivion by 6.0% during the 4th quarter. Entropy Technologies LP now owns 5,504 shares of the company's stock worth $251,000 after acquiring an additional 310 shares during the period. Van ECK Associates Corp boosted its position in shares of Artivion by 19.0% during the 3rd quarter. Van ECK Associates Corp now owns 3,176 shares of the company's stock valued at $134,000 after acquiring an additional 506 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after acquiring an additional 538 shares during the last quarter. Finally, MetLife Investment Management LLC grew its holdings in shares of Artivion by 2.7% in the fourth quarter. MetLife Investment Management LLC now owns 23,056 shares of the company's stock valued at $1,052,000 after purchasing an additional 606 shares during the period. Institutional investors and hedge funds own 86.37% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AORT. Weiss Ratings downgraded shares of Artivion from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Monday, June 8th. Canaccord Genuity Group reissued a "buy" rating and issued a $36.00 price objective on shares of Artivion in a research note on Tuesday, June 16th. Stifel Nicolaus set a $45.00 price objective on Artivion in a report on Monday, June 1st. Wall Street Zen lowered Artivion from a "buy" rating to a "hold" rating in a research report on Saturday, April 25th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $44.00 target price on shares of Artivion in a report on Monday, July 20th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $44.17.

About Artivion

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source